New trial
Phase 1 Dose Escalation Study of ZG006 in Small Cell Lung Cancer
- Trial ID
- NCT06592638 on ClinicalTrials.gov
- Cancer type
- Small-Cell Lung Cancer (SCLC)
- Location
- 2 Locations
- Published in
- New in Oncology - May 14, 2025
Suzhou Zelgen Biopharmaceuticals is evaluating ZG006—a DLL3 and CD3 directed bispecific mAb—in small cell lung cancer patients intolerant to standard treatment, using a 3+3 dose escalation design to determine the MTD/recommended dose.
More in small cell lung cancer
-
New trial · Oct 15, 2026 · NCT07625644
Phase 3 BrenDeLL-Lung01 tests DLL3-targeted BL-M14D1 plus atezolizumab in first-line extensive-stage SCLC -
New trial · Oct 1, 2026 · NCT07339059
Phase 2 sacituzumab govitecan TROP2-directed SN-38 ADC + PD-L1 blockade maintenance in ES-SCLC -
New trial · Sep 10, 2026 · NCT07778316
Phase 3 tarlatamab (Amgen) DLL3×CD3 bispecific T‑cell engager compares SC vs IV dosing -
New trial · Sep 3, 2026 · NCT07365241
Phase 3 ABBV-706 SEZ6-targeted topo-1 ADC vs chemotherapy in R/R SCLC -
Trial result · Aug 13, 2026
LIPI strongly stratifies survival in ES-SCLC but does not predict chemo-IO benefit